MAPT and Mental deterioration: Since tau pathology is the key driver of neurodegeneration and cognitive decline in AD (La Joie et al., 2020; Biel et al., 2021; Ossenkoppele et al., 2021b), understanding the cellular and molecular mechanisms underlying the different spatial patterns of tau distribution that sustained the diverse clinical manifestation of the disease could pave the way to develop new therapies that prevent cell death and memory deficits.